A carregar...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2020
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/ https://ncbi.nlm.nih.gov/pubmed/33316104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|